143 related articles for article (PubMed ID: 15327593)
1. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
de Graaf L; Brouwers AH; Diemont WL
Br J Clin Pharmacol; 2004 Sep; 58(3):326-8. PubMed ID: 15327593
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
de Langen JJ; van Puijenbroek EP
Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
[TBL] [Abstract][Full Text] [Related]
3. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
4. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Sebök B; Tóth M; Anga B; Harangi F; Schneider I
Acta Derm Venereol; 2004; 84(3):229-30. PubMed ID: 15202842
[No Abstract] [Full Text] [Related]
5. [Not just decreased LDL level is decisive. Which statin for patients at risk for coronary disease?].
MMW Fortschr Med; 2004 Jun; 146(24):1-3. PubMed ID: 15366507
[No Abstract] [Full Text] [Related]
6. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
7. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
[TBL] [Abstract][Full Text] [Related]
9. [High therapeutic effect and safety of fluvastatin].
Pharm Unserer Zeit; 2003; 32(6):516-7. PubMed ID: 14639833
[No Abstract] [Full Text] [Related]
10. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Milani M; Cimminiello C; Lorena M; Arpaia G; Soncini M; Bonfardeci G
Biomed Pharmacother; 1996; 50(6-7):269-74. PubMed ID: 8952866
[TBL] [Abstract][Full Text] [Related]
11. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
12. Fluvastatin and cancer.
Mascitelli L; Pezzetta F
Int J Clin Pract; 2007 Jan; 61(1):168; author reply 168-9. PubMed ID: 17229191
[No Abstract] [Full Text] [Related]
13. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
14. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
15. Statins and cancer development.
Duncan RE; El-Sohemy A; Archer MC
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1897-8. PubMed ID: 16103434
[TBL] [Abstract][Full Text] [Related]
16. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.
Sakamoto K; Honda T; Yokoya S; Waguri S; Kimura J
FASEB J; 2007 Dec; 21(14):4087-94. PubMed ID: 17634390
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hypercholesterolemia in kidney transplant recipients].
Fritsche L; Budde K; Neumayer HH
Dtsch Med Wochenschr; 2003 Apr; 128(16):879-81. PubMed ID: 12701034
[No Abstract] [Full Text] [Related]
18. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and short-term effects of pravastatin, a potent inhibitor of HMG-Co A reductase, on hypercholesterolemia in climacteric women.
Ushiroyama T; Ikeda A; Ueki M; Sugimoto O
J Med; 1994; 25(5):319-31. PubMed ID: 7730737
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
